Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?

被引：10

作者：

Lacerda Gontijo, Aline Vidal ^{[1
]}

Pereira, Sharlene Lopes ^{[1
]}

Bonfante, Herval de Lacerda ^{[1
,2
,3
]}

机构：

[1] Fed Univ Juiz de Fora UFJF, Inst Biol Sci, Dept Pharmacol, Rua Jose Lourenco Kelmer S-N, BR-36036900 Juiz De Fora, MG, Brazil

[2] Hosp Santa Casa Misericordia Juiz de Fora SCMJF, Div Rheumatol, Juiz De Fora, MG, Brazil

[3] Hlth Juiz de Fora SUPREMA, Sch Med Sci, Dept Internal Med, Juiz De Fora, MG, Brazil

来源：

CURRENT MICROBIOLOGY | 2022年 / 79卷 / 01期

关键词：

IN-VITRO ACTIVITY; FUSIDIC ACID; COLORECTAL-CANCER; MITOMYCIN-C; CLINICAL PHARMACOKINETICS; MITOTANE; 5-FLUOROURACIL; FLUOROURACIL; SPECTRUM; COLISTIN;

D O I：

10.1007/s00284-021-02693-5

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Carbapenem-resistant Acinetobacter baumannii has been classified as a top priority for the development of new therapies due to its resistance to most antibiotics. Drug repurposing may be a fast and inexpensive strategy for treating this pathogen. This review aims to critically evaluate repurposed drugs for the treatment of infections caused by carbapenem-resistant A. baumannii, correlating their antimicrobial activity with data available for toxicity and side effects. Some drugs have been suggested as promising candidates for repurposing; however, in some cases, high toxicity and low plasma concentrations reduce applicability in clinical practice. The most favorable applicability is offered by fusidic acid and colistin, possibly combined with a third agent, promising to be well tolerated and achieving satisfactory plasma concentrations.

引用

页数：12

共 87 条

[1] Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features [J].

Almasaudi, Saad B. .

SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2018, 25 (03) :586-596

[2] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update [J].

Amstutz, Ursula ;

Henricks, Linda M. ;

Offer, Steven M. ;

Barbarino, Julia ;

Schellens, Jan H. M. ;

Swen, Jesse J. ;

Klein, Teri E. ;

McLeod, Howard L. ;

Caudle, Kelly E. ;

Diasio, Robert B. ;

Schwab, Matthias .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) :210-216

[3] In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18 [J].

Appalaraju, Boppe ;

Baveja, Sujata ;

Baliga, Shrikala ;

Shenoy, Suchitra ;

Bhardwaj, Renu ;

Kongre, Vaishali ;

Dattatraya, Gogi Suresh ;

Dhole, Tapan ;

Verma, Binita ;

Mukherjee, D. N. ;

Gupta, Shalini ;

Shanmugam, Priyadarshini ;

Iravane, Jyoti ;

Mishra, Sudhi Ranjan ;

Barman, Purabi ;

Chopra, Shimpi ;

Hariharan, Meenakshi ;

Surpam, Rajendra ;

Pratap, Rana ;

Joshi, Prashant ;

Khande, Hemant ;

Mane, Ashish ;

Jain, Rishi ;

Bhagwat, Sachin .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) :600-608

[4] Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae [J].

Ayerbe-Algaba, Rafael ;

Luisa Gil-Marques, Maria ;

Enrique Jimenez-Mejias, Manuel ;

Sanchez-Encinales, Viviana ;

Parra-Millan, Raquel ;

Eugenia Pachon-Ibanez, Maria ;

Pachon, Jeronimo ;

Smani, Younes .

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2018, 8

[5] Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence [J].

Bhagwat, Sachin S. ;

Nandanwar, Manohar ;

Kansagara, Atul ;

Patel, Anusuya ;

Takalkar, Swapna ;

Chavan, Rajesh ;

Periasamy, Hariharan ;

Yeole, Ravindra ;

Deshpande, Prasad K. ;

Bhavsar, Satish ;

Bhatia, Ashima ;

Ahdal, Jaishid ;

Jain, Rishi ;

Patel, Mahesh .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 :4351-4365

[6]

Bocci G, 2000, CLIN CANCER RES, V6, P3032

[7] In Vitro Activity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant Acinetobacter baumannii Clinical Strains [J].

Bowler, Sarah L. ;

Spychala, Caressa N. ;

McElheny, Christi L. ;

Mettus, Roberta T. ;

Doi, Yohei .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (08) :5101-5101

[8] 5-Fluorouracil and Capecitabine Assessment and treatment of uncommon early-onset severe toxicities associated with administration [J].

Brutcher, Edith ;

Christensen, Deb ;

Smith, Melissa Hennessey ;

Koutlas, Judy B. ;

Sellers, Jean B. ;

Timmons, Tahitia ;

Thompson, Joanna .

CLINICAL JOURNAL OF ONCOLOGY NURSING, 2018, 22 (06) :627-634

[9] Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial [J].

Burock, Susen ;

Daum, Severin ;

Troger, Hanno ;

Kim, Theo Daniel ;

Kruger, Sandrine ;

Rieke, Damian Tobias ;

Ochsenreither, Sebastian ;

Welter, Kerstin ;

Herrmann, Pia ;

Sleegers, Arthur ;

Walther, Wolfgang ;

Keilholz, Ulrich ;

Stein, Ulrike .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[10] Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial [J].

Burock, Susen ;

Daum, Severin ;

Keilholz, Ulrich ;

Neumann, Konrad ;

Walther, Wolfgang ;

Stein, Ulrike .

BMC CANCER, 2018, 18

← 1 2 3 4 5 6 7 8 9 →